Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
Pharmaceutical Technology on MSN
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...
It was the priciest biotech startup sale in North Carolina history. Now five years under Bayer, AskBio advances more AAV gene ...
MeiraGTx Holdings Receives RMAT Designation from FDA for AAV-GAD Gene Therapy in Parkinson's Disease
MeiraGTx Holdings plc announced that the FDA has granted its investigational gene therapy AAV-GAD the Regenerative Medicine Advanced Therapy (RMAT) designation for treating Parkinson's disease ...
At a median 13 years after a single infusion of AAV-mediated gene therapy, factor IX expression remained stable in 10 patients with severe hemophilia B. The median annualized bleeding rate decreased ...
“We’re excited to share our latest data with the scientific community at ASGCT, which remains the most prestigious venue for showcasing gene therapy innovations,” said Dr. Nicole K. Paulk, PhD, Siren ...
Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and ...
The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback